ES2193615T3 - .nhibidor de la angiogenesis. - Google Patents

.nhibidor de la angiogenesis.

Info

Publication number
ES2193615T3
ES2193615T3 ES99106760T ES99106760T ES2193615T3 ES 2193615 T3 ES2193615 T3 ES 2193615T3 ES 99106760 T ES99106760 T ES 99106760T ES 99106760 T ES99106760 T ES 99106760T ES 2193615 T3 ES2193615 T3 ES 2193615T3
Authority
ES
Spain
Prior art keywords
angiogenesis
formula
compounds
cysteine protease
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99106760T
Other languages
English (en)
Inventor
Chiho Fukiage
Mitsuyoshi Azuma
Jun Inoue
Masayuki Nakamura
Yuka Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2193615T3 publication Critical patent/ES2193615T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBE UN INHIBIDOR DE LA ANGIOGENESIS QUE COMPRENDE UN COMPUESTO INHIBIDOR DE LA PROTEASA DE LA CISTEINA. COMO COMPUESTO PREFERIBLE INHIBIDOR DE LA PROTEASA DE LA CISTEINA, PUEDEN UTILIZARSE COMPUESTOS DE ACIDO EPOXISUCCINICO, COMPUESTOS DE HALOHIDRAZIDA DE PEPTIDOS, COMPUESTOS INHIBIDORES DEL CALPAIN, COMPUESTOS DE LA FORMULA (I) Y COMPUESTOS DE LA FORMULA (VI) EL INHIBIDOR DE LA ANGIOGENESIS DE LA PRESENTE INVENCION SUPRIME LA NEOFORMACION DE VASOS SANGUINEOS EN LOS TEJIDOS VIVOS, POR LO QUE PUEDE UTILIZARSE COMO EXCELENTE AGENTE TERAPEUTICO O PROFILACTICO DE LA ANGIOGENESIS ASOCIADA A CURACION DE HERIDAS, INFLAMACION, CRECIMIENTO DE TUMORES Y SIMILARES; Y LA ANGIOGENESIS QUE SE OBSERVA EN LA RETINOPATIA DIABETICA, LA RETINOPATIA DEL PREMATURO, LA OCLUSION VENOSA RETINIANA, LA DEGENERACION MACULAR DISCOIDE SENIL Y SIMILARES, ASI COMO PARA LA PREVENCION DE LA METASTASIS DE TUMORES.
ES99106760T 1995-10-25 1996-10-23 .nhibidor de la angiogenesis. Expired - Lifetime ES2193615T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27748595 1995-10-25
JP24804696 1996-09-19

Publications (1)

Publication Number Publication Date
ES2193615T3 true ES2193615T3 (es) 2003-11-01

Family

ID=26538555

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99106760T Expired - Lifetime ES2193615T3 (es) 1995-10-25 1996-10-23 .nhibidor de la angiogenesis.
ES99102501T Expired - Lifetime ES2190139T3 (es) 1995-10-25 1996-10-23 Inhibidor de la angiogenesis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99102501T Expired - Lifetime ES2190139T3 (es) 1995-10-25 1996-10-23 Inhibidor de la angiogenesis.

Country Status (13)

Country Link
US (2) US6057290A (es)
EP (2) EP0771565B1 (es)
AR (1) AR004694A1 (es)
AT (3) ATE239698T1 (es)
AU (1) AU716495B2 (es)
BR (1) BR9605267A (es)
CA (1) CA2188817C (es)
DE (3) DE69625622T2 (es)
ES (2) ES2193615T3 (es)
HU (1) HUP9602943A3 (es)
MX (1) MX9605156A (es)
NO (1) NO964514L (es)
PL (1) PL316669A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003060A1 (en) * 1995-07-13 1997-01-30 Senju Pharmaceutical Co., Ltd. Piperazine derivatives and use of the same
US6214800B1 (en) * 1995-10-25 2001-04-10 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
DE69815137T2 (de) * 1997-09-04 2004-04-08 Nippon Chemiphar Co. Ltd. Epoxybernsteinsäureamid-derivate
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
ATE400277T1 (de) 1998-03-05 2008-07-15 Senju Pharma Co Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
BR9908948A (pt) * 1998-03-20 2000-11-21 Senju Pharma Co Composição farmacêutica contendo um inibidor de protease cisteìna para profilaxia e terapia de dano ao tecido cerebral
GB9819860D0 (en) * 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
BR9916536A (pt) 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
AU3196300A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
KR20010001270A (ko) 1999-06-03 2001-01-05 복성해 혈관신생을 억제하는 새로운 이소쿠마린 유도체
WO2001026648A1 (en) 1999-10-13 2001-04-19 Senju Pharmaceutical Co., Ltd. Ophthalmic adhesive preparations for percutaneous absorption
AU1735001A (en) * 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
EP1334718A4 (en) * 2000-10-26 2007-07-18 Senju Pharma Co DRUG COMPOSITION CONTAINING DIPEPTIDYL ALDEHYDE COMPOUND
JPWO2002048096A1 (ja) * 2000-12-12 2004-04-15 千寿製薬株式会社 ヒドラゾン誘導体およびその医薬用途
CZ20033296A3 (cs) * 2001-06-06 2004-04-14 Eli Lilly And Company Benzoylsulfonamidy a sulfonylbenzamidiny jako protinádorové sloučeniny
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
KR101016593B1 (ko) * 2002-03-15 2011-02-22 센주 세이야꾸 가부시키가이샤 환식 반아세탈 유도체 및 이의 용도
WO2003082837A1 (en) 2002-03-29 2003-10-09 Senju Pharmaceutical Co., Ltd. Hydroxymorpholinone derivative and medicinal use thereof
EP1354586A1 (en) * 2002-04-20 2003-10-22 Aventis Pharma Deutschland GmbH The use of hydroxpyridone-derivatives in wound healing
US7022738B2 (en) * 2002-07-22 2006-04-04 Senju Pharmaceutical Co., Ltd. α-ketoamide derivative and use thereof
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
EP2541716A1 (en) 2010-02-25 2013-01-02 Panasonic Corporation Demand and supply control apparatus, demand and supply control method, and program
JP5823484B2 (ja) 2010-07-14 2015-11-25 千寿製薬株式会社 α―ケトアミド誘導体固体分散体
GB201218084D0 (en) 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
WO2019217410A1 (en) * 2018-05-07 2019-11-14 Neuro Theranostics, Inc. Compositions and methods for treating traumatic brain injury
US20240150396A1 (en) * 2021-03-03 2024-05-09 The Texas A&M University System Inhibitors of cysteine proteases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50137951A (es) 1974-04-27 1975-11-01
JPS5754157A (en) 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
JPH0832698B2 (ja) * 1987-05-08 1996-03-29 日本ケミファ株式会社 ピペラジン誘導体
JP2536754B2 (ja) * 1987-05-08 1996-09-18 日本ケミファ株式会社 ピペラジン誘導体
JP2701932B2 (ja) 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5510531A (en) 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
EP0395309B1 (en) * 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
JPH06506921A (ja) 1991-02-22 1994-08-04 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 置換α−アミノアルデヒドおよび誘導体
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5607831A (en) 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
AU3534195A (en) * 1994-09-27 1996-04-19 Takeda Chemical Industries Ltd. Aldehyde derivatives as upsteine protease inhibitors
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
EP0731107A1 (en) * 1995-02-13 1996-09-11 Takeda Chemical Industries, Ltd. Production of aldehyde derivatives
JPH11505532A (ja) 1995-05-10 1999-05-21 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
WO1997003060A1 (en) * 1995-07-13 1997-01-30 Senju Pharmaceutical Co., Ltd. Piperazine derivatives and use of the same
EP0910564B1 (en) 1995-11-28 2007-10-31 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases

Also Published As

Publication number Publication date
DE69625575T2 (de) 2003-09-25
AR004694A1 (es) 1999-03-10
EP0771565B1 (en) 2003-01-02
US6551999B1 (en) 2003-04-22
ATE230389T1 (de) 2003-01-15
DE69628050D1 (de) 2003-06-12
MX9605156A (es) 1998-05-31
NO964514L (no) 1997-04-28
US6057290A (en) 2000-05-02
HUP9602943A2 (en) 1997-08-28
EP0927716A1 (en) 1999-07-07
NO964514D0 (no) 1996-10-24
HUP9602943A3 (en) 1998-03-02
ATE230275T1 (de) 2003-01-15
CA2188817C (en) 2010-01-26
DE69625622T2 (de) 2003-08-14
EP0771565A2 (en) 1997-05-07
DE69625622D1 (de) 2003-02-06
AU7038496A (en) 1997-05-01
EP0771565A3 (en) 1998-11-04
ES2190139T3 (es) 2003-07-16
DE69628050T2 (de) 2004-04-01
DE69625575D1 (de) 2003-02-06
BR9605267A (pt) 1998-07-21
PL316669A1 (en) 1997-04-28
AU716495B2 (en) 2000-02-24
ATE239698T1 (de) 2003-05-15
EP0927716B1 (en) 2003-05-07
CA2188817A1 (en) 1997-04-26

Similar Documents

Publication Publication Date Title
ES2193615T3 (es) .nhibidor de la angiogenesis.
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
AR038605A1 (es) Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
HN1999000088A (es) Composiciones estabilizadas
ES2136307T3 (es) Procedimiento de fabricacion de papel tissue por medio de un agente de tratamiento.
AR023388A1 (es) INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO DE TRATAMIENTO
CL2010000383A1 (es) Esteres y amida de acidos carboxilicos que contienen un agente anti-inflamatorio no esteroidal; composicion farmaceutica: y su uso como inhibidores de 5-lipoxigenasa para prevenir o aliviar edema de tejidos, inflamacion y congestion de la conjuntiva, de la nubosidad de la cornea y daños a tejidos oftalmicos (divisional sol. 3109-99).
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
AR109263A2 (es) Composición que comprende moxidectina
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
ES2170305T3 (es) Derivados de acido hidroxietilaminosulfamico n-sustituidos utiles como inhibidores de proteasas retroviricas.
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
BR9809306A (pt) Inibidores de protease
ES2182255T3 (es) Agente de blanqueo fluorescente.
CO4960655A1 (es) Nueva composicion y su uso
ES2155517T3 (es) Derivados del acido n-acetil-neuraminico y procedimientos para su preparacion.
AR021241A1 (es) Inhibidores de proteasas
PA8542501A1 (es) Composicion
SE0004101D0 (sv) New use